Compare Strategy Inc. (MSTR) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs Oruka Therapeutics Inc. Common Stock — how do they compare? Strategy Inc. trades at $141 (market cap $64.44B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Strategy Inc. is far larger — about 12.4× Oruka Therapeutics Inc. Common Stock's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 113 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| MSTR | ORKA | |
|---|---|---|
Market Cap | $64.44B | $5.18B |
Volume | 12,273,653 | 490,798 |
Sector | Technology | Health |
52-Week High | $301.91 | $113.08 |
52-Week Low | $82.31 | $26.19 |
Typical Hold Time | 113 Days | 0 Days |
Enterprise Value | $83.20B | $4.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR stock trades at $143.24, down 6.18% today, with technical indicators showing neutral momentum near key support at $142. The company reported Q2 2026 EPS of -$24.45, missing expectations of -$2.19, continuing a trend of significant earnings misses. Despite negative profitability metrics including a -6,102.96% net income margin, analyst consensus remains bullish with 62% buy ratings and a $253.36 price target representing 77% upside potential from current levels.
The investment case hinges on analyst optimism despite fundamental challenges, with Citigroup recently doubling its price target to $240. Key risks include persistent negative earnings, high valuation multiples (P/S of 96.6), and substantial debt load of $7.19 billion. Cash flow trends show heavy reliance on financing activities to support operations and investments.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
